These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32202091)

  • 1. Universal Pharmacare in Canada: A Prescription for Equity in Healthcare.
    Hajizadeh M; Edmonds S
    Int J Health Policy Manag; 2020 Mar; 9(3):91-95. PubMed ID: 32202091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Universal prescription drug coverage in Canada: Long-promised yet undelivered.
    Morgan SG; Boothe K
    Healthc Manage Forum; 2016 Nov; 29(6):247-254. PubMed ID: 27744279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Financial burden of household out-of-pocket expenditures for prescription drugs: cross-sectional analysis based on national survey data.
    McLeod L; Bereza BG; Shim M; Grootendorst P
    Open Med; 2011; 5(1):e1-9. PubMed ID: 22046212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. It Won't Be Easy: How to Make Universal Pharmacare Work in Canada.
    Lewis S
    Int J Health Policy Manag; 2020 Jan; 9(1):1-5. PubMed ID: 31902189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National Pharmacare in Canada: Equality or Equity, Accessibility or Affordability Comment on "Universal Pharmacare in Canada: A Prescription for Equity in Healthcare".
    Rawson NSB
    Int J Health Policy Manag; 2020 Dec; 9(12):524-527. PubMed ID: 32610769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated cost of universal public coverage of prescription drugs in Canada.
    Morgan SG; Law M; Daw JR; Abraham L; Martin D
    CMAJ; 2015 Apr; 187(7):491-497. PubMed ID: 25780047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stitching the gaps in the Canadian public drug coverage patchwork?: a review of provincial pharmacare policy changes from 2000 to 2010.
    Daw JR; Morgan SG
    Health Policy; 2012 Jan; 104(1):19-26. PubMed ID: 21978939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
    Morgan SG; Li W; Yau B; Persaud N
    CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The redistributive effect of the move from age-based to income-based prescription drug coverage in British Columbia, Canada.
    Hanley GE; Morgan S; Barer M; Reid RJ
    Health Policy; 2011 Jul; 101(2):185-94. PubMed ID: 21255859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distributional consequences of the transition from age-based to income-based prescription drug coverage in British Columbia, Canada.
    Hanley GE; Morgan S; Hurley J; van Doorslaer E
    Health Econ; 2008 Dec; 17(12):1379-92. PubMed ID: 18189226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canadian pharmacare: looking back, looking forward.
    Morgan SG; Daw JR
    Healthc Policy; 2012 Aug; 8(1):14-23. PubMed ID: 23968600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Federal budget disappoints on universal pharmacare.
    Vogel L
    CMAJ; 2019 Apr; 191(14):E406-E407. PubMed ID: 30962204
    [No Abstract]   [Full Text] [Related]  

  • 13. Understanding the Battle for Universal Pharmacare in Canada Comment on "Universal Pharmacare in Canada".
    Gagnon MA
    Int J Health Policy Manag; 2021 Mar; 10(3):168-171. PubMed ID: 32610789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs?
    Coombes ME; Morgan SG; Barer ML; Pagliccia N
    Healthc Q; 2004; 7(4):suppl 13-9. PubMed ID: 15540402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare.
    Brandt J; Shearer B; Morgan SG
    J Pharm Policy Pract; 2018; 11():28. PubMed ID: 30443371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Challenges of Canadian Pharmacare Are More Complicated Than Acknowledged Comment on "Pharmacare in Canada".
    Acri Née Lybecker KML
    Int J Health Policy Manag; 2021 Mar; 10(3):152-154. PubMed ID: 32610780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The financial burden of prescription drugs for neurological conditions in Canada: Results from the National Population Health Study of Neurological Conditions.
    Guilcher S; Munce S; Conklin J; Packer T; Verrier M; Marras C; Bereket T; Versnel J; Riopelle R; Jaglal S
    Health Policy; 2017 Apr; 121(4):389-396. PubMed ID: 28215356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries.
    Kennedy J; Morgan S
    Clin Ther; 2009 Jan; 31(1):213-9. PubMed ID: 19243719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should national pharmacare apply a value-based insurance design?
    Yeung K; Morgan SG
    CMAJ; 2019 Jul; 191(29):E811-E815. PubMed ID: 31332049
    [No Abstract]   [Full Text] [Related]  

  • 20. Prescription drug coverage among elderly and disabled Americans: can Medicare-Part D reduce inequities in access?
    Kanavos P; Gemmill-Toyama M
    Int J Health Care Finance Econ; 2010 Sep; 10(3):203-18. PubMed ID: 20213234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.